Tezepelumab produced histologic remission in up to 68.9% of patients aged 12+ with EoE vs 3.5% with placebo at week 24, sustained to week 52.
News|Articles|October 1, 2026
Clinical trial news in pediatrics: September 2026
Author(s)Morgan Ebert, Executive Editor
Fact checked by: Benjamin P. Saylor
A recap of the top clinical trial and pipeline data readouts affecting pediatric care during September 2026.
Advertisement
Advertisement
September 2026's pediatric clinical trial readouts clustered heavily around growth and metabolic disorders. Three skeletal dysplasia programs — two in achondroplasia and one in hypochondroplasia — reported growth-velocity gains, while two GLP-1-class agents posted substantial BMI reductions in adolescents and in children as young as 6. Rare pediatric epilepsy, kidney disease, and eosinophilic esophagitis trials each delivered positive secondary or post hoc results, and a post-exposure COVID-19 antiviral's supporting phase 3 data rounded out the month.
Related to this article
In phase 3 SHINE-2, 50% of mirikizumab induction responders aged 6 to 17 with moderate to severe UC were in clinical remission at week 52.
Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.
Diana F. Clarke, PharmD, explains how IMPAACT 2023 supported dolutegravir from birth, plus dosing tips and open questions for preterm infants.
New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
Advertisement
Advertisement